AbCellera appoints Dr. Lynn Seely to Board of Directors as independent Class III director

AbCellera Biologics Inc.

Dr. Lynn Seely appointed as Class III director effective June 30, 2026, serving until 2029 annual meeting.
She is independent under Nasdaq rules and will receive standard non-employee director compensation.
Dr. Seely is President and CEO of Lyell Immunopharma, former CEO of Myovant Sciences, and former CMO of Medivation.
Her experience includes endocrinology, oncology, and women's health, relevant to AbCellera's antibody-based medicine development.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lynn Seely

Class III Director

ABCL · AbCellera Biologics Inc.

Effective: 2026-06-30
Filed: July 6, 2026, 2:53 PM ET

On June 30, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Lynn Seely, M.D as a new Class III director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lynn Seely was appointed as Class III Director at AbCellera Biologics Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On June 30, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Lynn Seely, M.D as a new Class III director.

View on SEC.gov

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001703057-26-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.